Effectiveness of CHIKV vaccine VLA1553 demonstrated by passive transfer of human sera

38Citations
Citations of this article
53Readers
Mendeley users who have this article in their library.

Abstract

Chikungunya virus (CHIKV) is a reemerging mosquito-borne alphavirus responsible for numerous outbreaks. Chikungunya can cause debilitating acute and chronic disease. Thus, the development of a safe and effective CHIKV vaccine is an urgent global health priority. This study evaluated the effectiveness of the live-attenuated CHIKV vaccine VLA1553 against WT CHIKV infection by using passive transfer of sera from vaccinated volunteers to nonhuman primates (NHP) subsequently exposed to WT CHIKV and established a serological surrogate of protection. We demonstrated that human VLA1553 sera transferred to NHPs conferred complete protection from CHIKV viremia and fever after challenge with homologous WT CHIKV. In addition, serum transfer protected animals from other CHIKV-associated clinical symptoms and from CHIKV persistence in tissue. Based on this passive transfer study, a 50% micro–plaque reduction neutralization test titer of ≥ 150 was determined as a surrogate of protection, which was supported by analysis of samples from a seroepidemiological study. In conclusion, considering the unfeasibility of an efficacy trial due to the unpredictability and explosive, rapidly moving nature of chikungunya outbreaks, the definition of a surrogate of protection for VLA1553 is an important step toward vaccine licensure to reduce the medical burden caused by chikungunya.

References Powered by Scopus

Chikungunya virus and the global spread of a mosquito-borne disease

645Citations
N/AReaders
Get full text

Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response

475Citations
N/AReaders
Get full text

Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages

437Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Chikungunya fever

78Citations
N/AReaders
Get full text

Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial

68Citations
N/AReaders
Get full text

Strategic considerations on developing a CHIKV vaccine and ensuring equitable access for countries in need

20Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Roques, P., Fritzer, A., Dereuddre-Bosquet, N., Wressnigg, N., Hochreiter, R., Bossevot, L., … Meinke, A. (2022). Effectiveness of CHIKV vaccine VLA1553 demonstrated by passive transfer of human sera. JCI Insight, 7(14). https://doi.org/10.1172/jci.insight.160173

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 10

53%

Researcher 8

42%

Professor / Associate Prof. 1

5%

Readers' Discipline

Tooltip

Immunology and Microbiology 8

44%

Biochemistry, Genetics and Molecular Bi... 6

33%

Agricultural and Biological Sciences 2

11%

Medicine and Dentistry 2

11%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free